Royalty Pharma plc (RPRX) Tops Q2 Revenue Estimate
Tweet
Share
E-mail
Get Alerts RPRX Hot Sheet
Price: $57.16 -0.82%
Financial Fact:
Research and development: 3.18M
Today's EPS Names:
TAYD, PKE, More
Financial Fact:
Research and development: 3.18M
Today's EPS Names:
TAYD, PKE, More
Join SI Premium – FREE
Royalty Pharma plc (NASDAQ: RPRX) reported Q2 cash receipts of $536 million versus the consensus estimate of $532.56 million.
GUIDANCE:
Royalty Pharma plc sees FY2022 adjusted cash receipts $2.275-2.35 billion, versus the consensus of $2.28 billion.
For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rivian reports record Q3 deliveries, beats estimates, shares rise
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Integra LifeSciences cuts 2026 outlook after Cincinnati flood
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
